Monofer (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monofer, is an intravenous iron preparation presented as an injection solution for intravenous infusion use. It is employed to treat iron deficiency anemia in adults and pediatric patients where oral iron is ineffective or not tolerated.

GNH USA supplies Monofer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, ensuring product integrity throughout the supply chain.

Monofer is indicated for conditions related to iron deficiency, where rapid repletion of iron stores is required.

- Iron deficiency anemia: restores hemoglobin levels and replenishes depleted iron stores in patients unable to absorb oral iron. - Chronic kidney disease‑associated anemia: provides intravenous iron to support erythropoiesis in patients receiving dialysis or ESA therapy. - Peri‑operative anemia: corrects iron deficiency before surgery to reduce transfusion requirements and improve postoperative recovery.

Monofer may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate feeling of sickness during or after infusion. - Headache: transient headache occurring shortly after administration. - Infusion site reactions: pain, erythema, or swelling at the injection site. - Transient hypotension: temporary drop in blood pressure during infusion.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Iron overload: excessive iron accumulation leading to organ dysfunction if dosing is inappropriate.

Prior to initiating Monofer therapy, clinicians should observe several precautionary measures to ensure patient safety. - Assess iron status: confirm iron deficiency with laboratory parameters before treatment. - Monitor hematology: regularly check hemoglobin, ferritin, and transferrin saturation during therapy. - Use under supervision: administer infusion in a setting equipped for emergency management of hypersensitivity. - Avoid in known hypersensitivity: contraindicated in patients with previous severe reactions to IV iron. - Caution with infection: defer treatment in active systemic infections until resolved. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Monofer can interact with certain medications, affecting iron metabolism or increasing the risk of adverse events.

Major Interactions (Avoid): - Concurrent IV iron products: may cause iron overload and heightened hypersensitivity risk. - High‑dose vitamin C: can increase free iron levels, potentially leading to oxidative damage.

Moderate Interactions (Monitor Closely): - Oral iron supplements: may augment total iron load; timing should be coordinated. - Antacids or calcium supplements: can reduce iron absorption if given simultaneously. - Erythropoiesis‑stimulating agents: monitor hemoglobin response to avoid excessive erythropoiesis.